Clazosentan disappointment for Actelion will prompt Conscious decision within month
This article was originally published in Scrip
Executive Summary
Actelion, one of Europe's leading biopharmaceutical companies, may have to abandon one of its Phase III programmes after unveiling disappointing results from a study of clazosentan for aneurismal subarachnoid haemorrhage (aSAH). While analysts had a pretty dim view of the molecule's chances of success and so had assigned very little value to the programmes, the company's share price still dropped CHF4.18 to CHF39.28 (9.6%), wiping CHF540 million ($550 million) off the company's value.